OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE PUMP
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE PUMP
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT

KETARX PATCH

Ketamine Microneedle Patch
PharmaTher has successfully completed the evaluation of a patented hydrogel-forming microneedle patch to deliver Ketamine as a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders. This de-risking milestone supports the Company’s expansion in finalizing IND-enabling studies and the clinical manufacturing scale up with LTS Lohmann, a leader in transdermal delivery systems, to support FDA and international regulatory submissions. Validation and tech transfer activities to support clinical studies are in progress.
Picture
Picture

Connect With Us

Picture
Picture
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario  Canada
M5C 1P1
Psychedelic Pharmaceuticals

COMPANY  /  RESEARCH  /  INVESTORS  /  NEWS  /  CONTACT


Publicly-traded on the OTCQB: PHRRF and CSE: PHRM
© COPYRIGHT 2023.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.